SIC
XENE icon

SJS Investment Consulting’s Xenon Pharmaceuticals XENE Stock Holding History

SJS Investment Consulting’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23K Buy
+37
New +$2.05K ﹤0.01% 1732
2024
Q2 		– Sell
-5
Closed -$216 – 1713
2024
Q1 		$216 Hold
5
– – ﹤0.01% 1472
2023
Q4 		$231 Buy
5
+2
+67% +$71 ﹤0.01% 1432
2023
Q3 		$103 Buy
3
+1
+50% +$37 ﹤0.01% 1539
2023
Q2 		$77 Buy
+2
New +$80 ﹤0.01% 1539

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SJS Investment Consulting's XENE Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 37 shares worth $2.23K. The stake represents ﹤0.01% of the portfolio and ranks #1732 among its holdings. This is a return to the name: SJS Investment Consulting previously reported a position in XENE as recently as Q1 2024.

SJS Investment Consulting first reported a position in XENE in Q2 2023 and has held it in 5 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • SJS Investment Consulting held 37 shares of Xenon Pharmaceuticals worth $2.23K as of Q2 2026.
  • Xenon Pharmaceuticals was a new SJS Investment Consulting position in Q2 2026.
  • Xenon Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1732 holding.
  • SJS Investment Consulting first reported a position in Xenon Pharmaceuticals in Q2 2023 and has held it in 5 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.